Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001)
Public ClinicalTrials.gov record NCT07321028. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of In-Vitro Cryo Therapeutic Intervention on Human Cellular Samples - Truway Health Cryogenics Pilot Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This laboratory-based study evaluates the effects of controlled cryogenic preservation on human cell samples using Truway Health's in-vitro cryo therapeutic methodology. The study analyzes post-thaw viability, functional recovery, and morphological integrity following exposure to different cryopreservation parameters. Findings will support optimization of cryogenic protocols intended for future translational, biobanking, and therapeutic applications.
Study identification
- NCT ID
- NCT07321028
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 50 participants
Conditions and interventions
Conditions
- Cellular Injury and Post-Cryogenic Recovery
- Cryogenic Cellular Stress
- Cold-Induced Cellular Injury
- Thermal Injury Response
- Post-Thaw Viability Impairment
- Osmotic Stress Injury
- Biomechanical Injury Modeling (In-Vitro)
- Blunt Force Injuries to the Extremities (Cellular Injury Model)
- Tissue Damage and Recovery Pathways
- Hypothermic Tissue Stress
- Cellular Regeneration and Repair
Interventions
- Standard Laboratory Cryopreservation Procedure Other
- Enhanced Laboratory Cryopreservation Procedure Other
- Normothermic Cell Culture Control Other
Other
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 9, 2025
- Primary completion
- Dec 9, 2066
- Completion
- Dec 9, 2066
- Last update posted
- Jan 5, 2026
2025 – 2066
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016 | New York | New York | 10016 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07321028, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07321028 live on ClinicalTrials.gov.